Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files Form 6-K current reports under the Securities Exchange Act of 1934, along with registration statements on Form F-3 and Form S-8 referenced in those reports. These filings document key events in the company’s development as a commercial-stage medical device and diagnostics business focused on respiratory support and blood monitoring.
Recent Form 6-K reports describe transactions such as a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement that together outline Inspira’s equity financing tools. Other 6-Ks incorporate press releases on clinical and regulatory milestones, including progress with the HYLA non-invasive blood sensor, regulatory steps for the INSPIRA ART100 system in the United Arab Emirates, and financial results and business updates. Filings also cover shareholder meeting materials, board and executive changes, and adjustments to sales agreements for ordinary shares.
Through this page, users can review Inspira’s SEC-reported information on capital structure, financing arrangements, and material operational updates. Stock Titan’s tools can surface new 6-K submissions in real time and help summarize their contents, allowing readers to quickly understand how each filing relates to topics such as product commercialization, clinical studies, or corporate governance. For deeper analysis, investors can examine attachments referenced in the 6-Ks, including financial statements, management’s discussion and analysis, and opinions related to securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. has established a wholly owned subsidiary as part of a revised corporate structure. The company plans to transfer its existing medical business activities into this new entity, concentrating its operating business under the subsidiary.
The report is also incorporated by reference into Inspira Technologies’ existing Form F-3 and Form S-8 registration statements, so that these U.S. securities filings reflect the updated corporate structure from the date of this report.
Inspira Technologies OXY B.H.N. Ltd executive Shabtay Abraham, the COO and VP of R&D, filed an initial ownership report showing his equity position in the company. He directly holds 1,332,713 ordinary shares, plus employee share options over 57,144 and 38,095 ordinary shares at an exercise price of $0.12 per share, expiring on April 20, 2030. His holdings also include multiple restricted stock unit grants that vest quarterly through early 2028 and additional RSUs that vest upon milestone achievements, reflecting a compensation package strongly tied to the company’s long-term performance.
Inspira Technologies OXY B.H.N. Ltd reported the initial holdings of its Chief Financial Officer, Tehila Yafit. She directly holds 946,395 ordinary shares, which include multiple restricted stock unit (RSU) grants that vest through February 1, 2028 and upon certain milestones.
She also holds employee share options over 13,605 ordinary shares with an exercise price of $0.12 per share. These options were granted on February 21, 2021, became fully vested as of February 23, 2024, and expire on February 21, 2031.
Inspira Technologies OXY B.H.N. Ltd director Tal Parnes filed an initial ownership report showing equity holdings in the company. Parnes directly holds 210,000 ordinary shares, plus share options covering 4,701 ordinary shares at an exercise price of $0.1200 per share, with expiration on April 20, 2030. The position also includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 100,001 restricted stock units vesting quarterly until February 1, 2028, indicating a mix of current ownership and future potential shares through options and RSUs.
Inspira Technologies OXY B.H.N. Ltd director Matza Sivan filed an initial ownership report showing beneficial ownership of 30,000 ordinary shares. These include 9,999 restricted stock units that vest on October 21, 2026 and 20,001 restricted stock units that vest quarterly from January 21, 2027 until October 21, 2028.
Inspira Technologies OXY B.H.N. Ltd director Amit Lior filed an initial ownership report showing beneficial ownership of 61,667 ordinary shares. This includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 20,001 restricted stock units vesting quarterly until February 1, 2028, all held directly.
Inspira Technologies OXY B.H.N. Ltd Chief Technology Officer Daniella Yechezkely Hayon reported beneficial ownership of 830,000 ordinary shares as of the reported date. This is an initial ownership filing rather than a new trade.
The position includes restricted stock units: 36,667 RSUs vesting quarterly until February 1, 2027, 100,001 RSUs vesting quarterly until February 1, 2028, 100,000 RSUs vesting on July 1, 2026, 200,000 RSUs vesting quarterly beginning October 1, 2026 until July 1, 2028, and 100,000 RSUs that vest upon achieving specified milestones.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 showing Chief Executive Officer Ben-Noon Dagi Shahar as the beneficial owner of 2,927,239 ordinary shares held directly. This holding includes restricted stock units scheduled to vest quarterly through February 1, 2027 and February 1, 2028.
The filing also reports employee share options covering 57,159 ordinary shares with a converted exercise price of $0.12 per share. These options were granted on November 1, 2020, became fully vested as of January 1, 2021, and are exercisable until April 20, 2030.
Inspira Technologies OXY B.H.N. Ltd reports a 5.2% beneficial ownership stake held by Dagi Ben-Noon. The reporting person beneficially owns 2,297,730 ordinary shares as of 12/31/2025, comprised of 326,739 shares, 1,913,832 RSUs vested or vesting within 60 days, and 57,159 options exercisable within 60 days. The percentage is based on 43,916,997 outstanding ordinary shares.
Inspira Technologies Oxy B.H.N. Ltd. reports two key updates. First, it amended its senior convertible debenture with Bio-View Ltd., extending the deadline to satisfy certain prerequisites from 45 to 75 days and revising the required $5,000,000 investment so it must come from investors introduced under a placement agreement with A.G.P/ Alliance Global Partners.
Second, Inspira received a Nasdaq notice that it is not meeting the minimum market value of publicly held shares requirement of $35,000,000. The company has 180 days, until August 18, 2026, for its market value of publicly held shares to reach at least $35,000,000 for 10 consecutive business days, or its securities may face delisting unless a Nasdaq hearings panel grants relief.